Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

578
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
578
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

752
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
752
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

316
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
316
Drug Therapy01:28

Drug Therapy

153
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
153
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

317
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wearable Technologies for Healthy Ageing: Prospects, Challenges, and Ethical Considerations.

The Journal of frailty & aging·2024
Same author

Optimizing the Aging Brain: The BEAD Study on the Ethics of Dementia Prevention.

The Journal of frailty & aging·2023
Same author

Sporadic pedunculated duodenal adenomas. Clinical presentations and endoscopic management: a case series.

Il Giornale di chirurgia·2018
Same author

Search for Physics Beyond the Standard Model in Events with High-Momentum Higgs Bosons and Missing Transverse Momentum in Proton-Proton Collisions at 13 TeV.

Physical review letters·2018
Same author

Observation of tt[over ¯]H Production.

Physical review letters·2018
Same author

Search for Heavy Neutral Leptons in Events with Three Charged Leptons in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2018
Same journal

Distinct spatial patterns of perivascular spaces enlargement for multiple and Co-existing pathologies of cognitive impairment.

The journal of prevention of Alzheimer's disease·2026
Same journal

Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire.

The journal of prevention of Alzheimer's disease·2026
Same journal

The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population.

The journal of prevention of Alzheimer's disease·2026
Same journal

Asia's dementia burden: from epidemiological description to prevention-oriented neurology.

The journal of prevention of Alzheimer's disease·2026
Same journal

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status.

The journal of prevention of Alzheimer's disease·2026
Same journal

Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.

The journal of prevention of Alzheimer's disease·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.5K

Overtreating Alzheimer's Disease.

M Canevelli1, N Vanacore, A Blasimme

  • 1Matteo Cesari, MD, PhD, Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Via Camaldoli 64 - 20138 Milan - Italy, Phone: +39 02 50725136, Twitter: @macesari,

The Journal of Prevention of Alzheimer'S Disease
|February 11, 2021
PubMed
Summary
This summary is machine-generated.

Managing frailty in older adults, especially those with Alzheimer's disease (AD), requires more than medication. Research must integrate aging and frailty into trials for real-world application.

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.6K
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

18.8K

Related Experiment Videos

Last Updated: Nov 17, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.5K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.6K
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

18.8K

Area of Science:

  • Geriatric Medicine
  • Neurodegenerative Diseases
  • Clinical Trial Design

Background:

  • Frailty management in older persons is complex, often hindered by biological, clinical, and social factors.
  • Frailty significantly impacts evidence-based medicine in geriatric care.
  • Patients with Alzheimer’s disease (AD) are increasingly older and frailer, with higher polypharmacy rates.

Purpose of the Study:

  • To address the challenges in translating research evidence into clinical practice for frail older adults.
  • To advocate for research designs that incorporate aging and frailty in Alzheimer’s disease (AD) clinical trials.
  • To caution against an overemphasis on early AD detection that may neglect patient values.

Main Methods:

  • Review of current challenges in geriatric frailty management.
  • Analysis of the impact of frailty on evidence-based medicine in AD care.
  • Discussion on the need for integrated research approaches.

Main Results:

  • Frailty is a major barrier to implementing evidence-based medicine in geriatrics.
  • Current AD research trends may overlook patient-centered care by focusing solely on early disease detection.
  • A gap exists between research findings and practical clinical application in frail populations.

Conclusions:

  • Clinical trials must integrate aging and frailty to yield implementable results for real-world geriatric care.
  • Over-focusing on early AD detection risks overshadowing individual patient values and priorities.
  • Clinicians should avoid unsupported pharmacological prescriptions in frail older adults.